Journal article
TMPRSS2 inhibitors for the treatment of COVID-19 in adults: a systematic review and meta-analysis of randomized clinical trials of nafamostat and camostat mesylate
Maria Patricia Hernandez-Mitre, Susan C Morpeth, Balasubramanian Venkatesh, Thomas E Hills, Joshua Davis, Robert K Mahar, Grace McPhee, Mark Jones, James Totterdell, Steven YC Tong, Jason A Roberts
Clinical Microbiology and Infection (CMI) | Elsevier | Published : 2024
Abstract
Background: Synthetic serine protease inhibitors block the cellular enzyme transmembrane protease serine 2, thus preventing SARS-CoV-2 cell entry. There are two relevant drugs in this class, namely, nafamostat (intravenous formulation) and camostat (oral formulation). Objective: To determine whether transmembrane protease serine 2 inhibition with nafamostat or camostat is associated with a reduced risk of 30-day all-cause mortality in adults with COVID-19. Data sources: Scientific databases and clinical trial registry platforms. Study eligibility criteria, interventions, and participants: Preprints or published randomized clinical trials (RCTs) of nafamostat or camostat vs. usual care or pla..
View full abstractGrants
Awarded by Australian National Health and Medical Research Council for a Centre of Research Excellence
Funding Acknowledgements
JAR would like to acknowledge funding from the Australian National Health and Medical Research Council for a Centre of Research Excellence (APP2007007) and an Investigator Grant (APP2009736) as well as an Advancing Queensland Clinical Fellowship.